Toggle menu

Halt-It Trial

Start date:
August 2014
End date:
November 2016
Co-ordinated by:
London School of Hygiene and Tropical Medicine
Main trial site:
http://haltit.lshtm.ac.uk

HALT-IT trial, Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double blind placebo controlled trial

 

Aim

The HALT‐IT trial will determine the effect of early administration of TXA on mortality, morbidity (re‐bleeding, non‐fatal vascular events), blood transfusion, surgical intervention and health status in patients with acute gastrointestinal bleeding.

Trial Design

A pragmatic, randomised, double blind, placebo controlled trial among 8,000 patients with significant gastrointestinal bleeding.

Eligibility criteria

Patients with significant GI bleeds in whom the use of tranexamic acid is neither indicated nor contraindicated

Chief Investigator

Professor Iain Roberts (LSHTM)

Local PI

Dr Matt Reed (RIE)

Research Team

Dr Nick Church
Dr James Dear
Dr Kallirroi Kefala
Julia Grahamslaw – local EMeRGE study lead
ED research nurses

Local PI

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Research Team

Julia Grahamslaw

Lead Research Nurse

Bernadette Gallagher

Senior Research Nurse

More EMERGE Trials

CERA

COVID-19 Emergency Response Assessment. A Professional Survey

The RECOVERY Trial

Randomised Evaluation of COVID-19 Therapy

ISARIC4C – Coronavirus Clinical Characterisation Consortium, an observational study

ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK)